Cite
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
MLA
Lio, Peter A., et al. “Improvement in Sleep and Itch and Enhanced Quality of Life in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Phase 3 Trial of Baricitinib Therapy.” Journal of Dermatological Treatment, vol. 33, no. 4, June 2022, pp. 2057–62. EBSCOhost, https://doi.org/10.1080/09546634.2021.1914308.
APA
Lio, P. A., Simpson, E. L., Han, G., Soung, J., Ball, S., Sun, L., Casillas, M., DeLozier, A. M., Ding, Y., & Eichenfield, L. F. (2022). Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. Journal of Dermatological Treatment, 33(4), 2057–2062. https://doi.org/10.1080/09546634.2021.1914308
Chicago
Lio, Peter A., Eric L. Simpson, George Han, Jennifer Soung, Susan Ball, Luna Sun, Marta Casillas, Amy M. DeLozier, Yuxin Ding, and Lawrence F. Eichenfield. 2022. “Improvement in Sleep and Itch and Enhanced Quality of Life in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Phase 3 Trial of Baricitinib Therapy.” Journal of Dermatological Treatment 33 (4): 2057–62. doi:10.1080/09546634.2021.1914308.